AMAG Pharmaceuticals News

Scope of the reports Each Life Science AnalyticsA' Pipeline Report provides the user with real detail on a companyA's pipeline.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

AMAG Pharmaceuticals, Inc. today announced that three abstracts have been accepted for presentation at the American Society of Nephrology Renal Week meeting being held October 27-November 1, 2009 in San Diego, CA.

AMAG is based in Lexington. AMAG Pharmaceuticals Inc. fell after a Jefferies and Co.

BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Wednesday, September 30th, 2009 and come to the following statistical conclusions.

Sep 4, 2009 - AMAG Pharmaceuticals, Inc. today announced that its Board of Directors has adopted a Shareholder Rights Plan under which all shareholders of record as of September 17, 2009 will receive rights to purchase shares of a new series of Preferred Stock.

This report analyzes the Global Market for Nanomedicine in Millions of US$ by the following Application Areas: Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials, and Others.

BioTrends Research Group, Inc. released TreatmentTrends : US Nephrology , a syndicated report analyzing treatment practices, attitudes and perceptions based on online survey results from over 200 US Nephrologists.

BioTrends Research Group, Inc. released TreatmentTrends : US Nephrology , a syndicated report analyzing treatment practices, attitudes and perceptions based on online survey results from over 200 US Nephrologists.

AMAG Pharmaceuticals struck a cautious but optimistic tone Wednesday night about the nascent commercial launch of its intravenous iron replacement therapy Feraheme.

AMAG Pharmaceuticals, Inc. today announced it will report unaudited consolidated financial results for the quarter ended June 30, 2009 after the U.S. financial markets close on July 29, 2009.

NEWARK, Del.-- --U.S. stocks rose today as Dow Jones Industrial Average was up 185 points to close at 8331, S&P 500 gained 21 points to 901 and the Nasdaq Composite climbed 37 points to 1793.

AMAG Pharmaceuticals, Inc. today announced that Ferahemea Injection is now available for commercial sale in the United States.

AMAG Pharmaceuticals announced Tuesday that it has received FDA's approval to market ferumoxytol injection for the treatment of iron deficiency anemia in adults with chronic kidney disease.

Since 2002, David and Tom Gardner have returned 31.77% while the S&P 500 returned -9.90%. Try Stock Advisor free for 30 days.

AMAG Pharmaceuticals Inc. has won U.S. Food and Drug Administration approval for its drug, called Feraheme, to treat chronic kidney disease.

AMAG Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted marketing approval for Ferahemea Injection for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.

BOCA RATON, Fla.-- --Juniper Group, Inc. is pleased to announce that the operating revenues for the quarter ending June 30, 2009 of its wholly owned broadband subsidiary will exceed - NEW YORK-- --Fitch Ratings has assigned an 'F1' rating to Great Bridge Capital Company, LLC's asset-backed commercial paper .

It was a day late - but AMAG Pharmaceuticals Inc. will hardly end up any dollars short.

Sealy Corp. shares traded in volatile fashion Tuesday evening after the maker of mattresses surpassed most analysts' quarterly projections, while shares in AMAG Pharmaceuticals Inc.